scale. The described process starts from a commercially available indole-2-carboxylate and employs an Ellman auxiliary approach coupled with ruthenium-catalyzed stereoselective reduction for the introduction of chirality. The key spirocyclic cyclobutane motif was assembled utilizing an epoxide building block, which was conveniently obtained in diastereomerically pure form. The amount and quality of the
开发了一种用于制备
金属-β-内酰胺酶抑制剂预选物 EBL-3183 的新合成路线,并以千克规模进行。所描述的过程从市售的 indole-2-carboxylate 开始,并采用 Ellman 辅助方法与
钌催化的立体选择性还原相结合,以引入手性。关键的螺环
环丁烷基序是利用
环氧化物结构单元组装而成的,该结构单元可以方便地以非对映体纯形式获得。制备的最终靶标 EBL-3183 的数量和质量足以用于临床前研究。